[1] |
SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2021[J]. CA A Cancer J Clin, 2021, 71(1): 7-33.
|
[2] |
DUMA N, SANTANA-DAVILA R, MOLINA J R. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment[J]. Mayo Clin Proc, 2019, 94(8): 1623-1640.
doi: S0025-6196(19)30070-9
pmid: 31378236
|
[3] |
MILLER M, HANNA N. Advances in systemic therapy for non-small cell lung cancer[J]. BMJ, 2021, 375: n2363.
|
[4] |
DA CUNHA SANTOS G, SHEPHERD F A, TSAO M S. EGFR mutations and lung cancer[J]. Annu Rev Pathol, 2011, 6: 49-69.
|
[5] |
HARRISON P T, VYSE S, HUANG P H. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer[J]. Semin Cancer Biol, 2020, 61: 167-179.
doi: S1044-579X(19)30302-5
pmid: 31562956
|
[6] |
LIM S M, SYN N L, CHO B C, et al. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies[J]. Cancer Treat Rev, 2018, 65: 1-10.
doi: S0305-7372(18)30016-1
pmid: 29477930
|
[7] |
LI W H, QIU T, GUO L, et al. Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment[J]. Cancer Lett, 2018, 423: 9-15.
|
[8] |
RIZVI N A, HELLMANN M D, SNYDER A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230): 124-128.
doi: 10.1126/science.aaa1348
pmid: 25765070
|
[9] |
ISOMOTO K, HARATANI K, HAYASHI H, et al. Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer[J]. Clin Cancer Res, 2020, 26(8): 2037-2046.
|
[10] |
GUEGUEN P, METOIKIDOU C, DUPIC T, et al. Contribution of resident and circulating precursors to tumor-infiltrating CD8+ T cell populations in lung cancer[J]. Sci Immunol, 2021, 6(55): eabd5778.
|
[11] |
PATIL N S, NABET B Y, MÜLLER S, et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer[J]. Cancer Cell, 2022, 40(3): 289-300.e4.
doi: 10.1016/j.ccell.2022.02.002
pmid: 35216676
|
[12] |
JIN Y, XUE Q Q, SHEN X X, et al. PD-L1 expression and comprehensive molecular profiling predict survival in non-small cell lung cancer: a real-world study of a large Chinese cohort[J]. Clin Lung Cancer, 2022, 23(1): 43-51.
|
[13] |
ZHENG Q, HUANG Y, ZENG X, et al. Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-worldstudy in China[J]. J Cancer Res Clin Oncol, 2021, 147(5): 1547-1556.
|
[14] |
WANG X, HUI S, TAN C, et al. Comprehensive analysis of immune subtypes reveals the prognostic value of cytotoxicity and FAP+ fibroblasts in stomach adenocarcinoma[J]. Cancer Immunol Immunother, 2023, 72(6): 1763-1778.
|
[15] |
CHEN Z, FILLMORE C M, HAMMERMAN P S, et al. Non-small cell lung cancers: a heterogeneous set of diseases[J]. Nat Rev Cancer, 2014, 14(8): 535-546.
|
[16] |
GELATTI A C Z, DRILON A, SANTINI F C. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)[J]. Lung Cancer, 2019, 137: 113-122.
doi: S0169-5002(19)30661-0
pmid: 31568888
|
[17] |
NEEL D S, BIVONA T G. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma[J]. NPJ Precis Oncol, 2017, 1: 3.
|
[18] |
DENIS M G, VALLÉE A, THÉOLEYRE S. EGFR T790M resistance mutation in non small-cell lung carcinoma[J]. Clin Chim Acta, 2015, 444: 81-85.
|
[19] |
WANG S Y, YAN B, ZHANG Y W, et al. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation[J]. Int J Cancer, 2019, 144(11): 2880-2886.
|
[20] |
AKBAY E A, KOYAMA S, CARRETERO J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors[J]. Cancer Discov, 2013, 3(12): 1355-1363.
|
[21] |
VOKES N I, CHAMBERS E, NGUYEN T, et al. Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma[J]. J Thorac Oncol, 2022, 17(6): 779-792.
|
[22] |
GOU L Y, LI A N, YANG J J, et al. The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer[J]. Oncotarget, 2016, 7(32): 51311-51319.
|
[23] |
ZALAQUETT Z, CATHERINE RITA HACHEM M, KASSIS Y, et al. Acquired resistance mechanisms to osimertinib: the constant battle[J]. Cancer Treat Rev, 2023, 116: 102557.
|
[24] |
BRUNO T C. New predictors for immunotherapy responses sharpen our view of the tumor microenvironment[J]. Nature, 2020, 577(7791): 474-476.
|
[25] |
HOU H L, QIN K, LIANG Y, et al. Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC[J]. Cancer Manag Res, 2019, 11: 5665-5675.
|
[26] |
OFFIN M, CHAN J M, TENET M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes[J]. J Thorac Oncol, 2019, 14(10): 1784-1793.
|
[27] |
BITON J, MANSUET-LUPO A, PÉCUCHET N, et al. TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma[J]. Clin Cancer Res, 2018, 24(22): 5710-5723.
|